<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135326</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0541</org_study_id>
    <secondary_id>NCI-2019-03834</secondary_id>
    <secondary_id>2018-0541</secondary_id>
    <nct_id>NCT04135326</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation in Reducing Pain in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy</brief_title>
  <official_title>Transcranial Direct Current Stimulation (tDCS) to Reduce Pain in Patients With Chemotherapy Induced Peripheral Neuropathy: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well transcranial direct current stimulation works in&#xD;
      reducing pain in cancer patients with chemotherapy induced peripheral neuropathy.&#xD;
      Transcranial direct current stimulation is used for patients with brain injuries such as&#xD;
      strokes as well as for mental health issues such as depression and may help to control pain&#xD;
      in cancer patients with chemotherapy induced peripheral neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the efficacy of transcranial direct current stimulation (tDCS) in reducing&#xD;
      chemotherapy induced painful peripheral neuropathy (CIPPN).&#xD;
&#xD;
      Ia. Evaluate the change in pain scores Ib. Assess for changes in other symptoms (i.e&#xD;
      insomnia, feeling of well-being, depression and anxiety).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the following with the treatment of tDCS:&#xD;
&#xD;
      Ia. Assess for changes in using pain medications. Ib. Assess for changes in functioning&#xD;
      (daily activities). Ic. Assess for changes in quality of life. Id. Assess for changes in&#xD;
      neuropathy. Ie. Assess overall satisfaction with the tDCS treatment.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate tDCS treatment related side-effects.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo tDCS once daily (QD) over 20 minutes 5 days each week (Monday-Friday) for 3&#xD;
      weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up weekly for 3 weeks and at 4-6&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Per PI termination request, no patients enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Actual">October 26, 2020</completion_date>
  <primary_completion_date type="Actual">October 26, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in chemotherapy induced peripheral neuropathy pain score</measure>
    <time_frame>Baseline up to final day of treatment (3 weeks)</time_frame>
    <description>The Pain inventory is an assessment of pain level on a 11-point numeric rating scales (0=none to 10=worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total opioid requirement (morphine equivalent daily dosage)</measure>
    <time_frame>Baseline up to 4-6 weeks post-treatment</time_frame>
    <description>Will be summarized using descriptive statistics including mean, standard deviation, median, range, and CIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cancer related symptoms</measure>
    <time_frame>Baseline up to 4-6 weeks post-treatment</time_frame>
    <description>We will analyze each patient's Pain Management Center Follow-Up/ Progress Notes and Standardize questionnaire which includes the assessment of the aforementioned symptoms on a 11-point numeric rating scales (0=none to 10=worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functioning of Daily Activities</measure>
    <time_frame>Baseline up to 4-6 weeks post-treatment</time_frame>
    <description>We will analyze each patient's Pain Management Center Follow-Up/ Progress Notes and Standardize questionnaire which includes the assessment of the aforementioned symptoms on a 11-point numeric rating scales (0=none to 10=worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life questionnaire</measure>
    <time_frame>Baseline up to 4-6 weeks post-treatment</time_frame>
    <description>We will analyze each patient's Pain Management Center Follow-Up/ Progress Notes and Standardize questionnaire which includes the assessment of the aforementioned symptoms on a 11-point numeric rating scales (0=none to 10=worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 4-6 weeks post-treatment</time_frame>
    <description>Frequency counts and percentages will be documented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chemotherapy-Induced Peripheral Neuropathy</condition>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Supportive care (tDCS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo tDCS QD over 20 minutes 5 days each week (Monday-Friday) for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (tDCS)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (tDCS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>Undergo tDCS</description>
    <arm_group_label>Supportive care (tDCS)</arm_group_label>
    <other_name>tDCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Able to give a Voluntary written consent.&#xD;
&#xD;
          -  Cancer patients with chemotherapy induced peripheral neuropathy of at least 3 months&#xD;
             duration..&#xD;
&#xD;
          -  Pain and/or tingling of at least 4/10&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  History of seizure&#xD;
&#xD;
          -  History of migraine headache&#xD;
&#xD;
          -  History of brain cancer and/or brain metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salahadin Abdi</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

